ISRCTN17142179进行中（未招募）3 期
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthma
Chiesi (Italy)0 个研究点目标入组 513 人开始时间: 2024年2月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 513
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 10/05/2024:
- •1. Male and female adults aged =18 and =75 years
- •2. Body mass index (BMI) within the range of 18.0 to 35.0 kg/m2
- •3. Physician-diagnosed asthma >6 months and diagnosis before 50 years
- •4. Stable asthma therapy: a stable treatment with medium/high doses of ICS+LABA+LAMA (fixed or free combination) or medium/high doses of ICS+LABA (fixed or free combination) for at least 4 weeks before screening
- •5. Asthma control: controlled or partly controlled based on an Asthma Control Questionnaire (ACQ-7) score <1.5 at screening and at randomization;
- •6. Pre-bronchodilator 40% < FEV1 < 90% of their predicted normal value, after appropriate washout from bronchodilators, at the screening and randomization;
- •7. Subjects with a positive reversibility test at screening defined as an increase = 12% and/or 200 mL within 15-20 minutes after inhalation of 400mcg salbutamol [ Note 1: To assess for BD response, pre-BD and post-BD spirometry must meet the acceptability and repeatability criteria as reported in the 2019 ATS/ERS Standardisation of Spirometry Update. Note 2: In case the BD response threshold is not met at a screening or if spirometry does not meet quality requirements, the spirometry test can be repeated no later than 1 day before randomisation at a second spirometry visit. In case the BD response is not met at this second spirometry visit or if spirometry does not meet quality requirements, historical documentation of BD response can be provided. Historical documentation of BD response, defined according to the 2005 American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines or history of positive bronchial challenge test (methacholine) within 24 months prior to screening, is also accepted. Copy of original printed spirometry or bronchial challenge test must be included as source documentation. ]
- •Previous inclusion criteria:
- •1. Male and female adults aged =18 and =75
- •2. Body mass index (BMI) within the range of 18.0 to 35.0 kg/m2
- •3. Physician-diagnosed asthma >6 months and diagnosis before 50 years
- •4. Stable asthma therapy: a stable treatment with medium/high doses of ICS+LABA+LAMA (fixed or free combination) or medium/high doses of ICS+LABA (fixed or free combination) for at least 4 weeks before screening
- •5. Asthma control: controlled or partly controlled based on an Asthma Control Questionnaire (ACQ-7) score <1.5 at screening and at randomization;
- •6. Pre-bronchodilator 40% < FEV1 < 90% of their predicted normal value, after appropriate washout from bronchodilators, at the screening and randomization;
- •7. Subjects with a positive reversibility test at screening defined as an increase = 12% and/or 200 mL within 15-20 minutes after inhalation of 400mcg salbutamol [ NOTE: in case the bronchodilator (BD) response threshold is not met at screening, the spirometry test can be repeated no later than 1 day before randomisation at a second spirometry visit. In case the BD response is not met at this second spirometry visit, historical documentation of the BD response can be provided. Historical documentation of BD response defined according to the 2005 American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force on interpretative strategies for lung function tests, or history of positive bronchial challenge test (methacholine) within 24 months prior to screening (copy of original printed spirometry to be included as source documentation) is also accepted. ]
排除标准
- •1. History of near-fatal asthma, hospitalisation for asthma in intensive care unit which in the judgement of the Investigator may place the subject at undue risk, emergency room access for asthma in the previous 6 months before enrolment
- •2. Asthma exacerbation requiring systemic corticosteroids (SCS) or emergency room admission or hospitalisation within 4 weeks prior to study entry and/or during the run-in period (to be checked again prior to randomisation)
- •3. Non-permanent asthma: exercise-induced, seasonal asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine
- •4. Asthma subjects currently treated with chronic SCS, anti-immunoglobulin E (IgE), or any other biologic therapy
- •5. Any concomitant respiratory disease that, in the opinion of the Investigator and/or Medical Monitor, will interfere with the evaluation of the investigational product or interpretation of subject safety or study results. This can include but is not limited to the diagnosis of chronic obstructive pulmonary disease (COPD) as defined by the current guidelines
研究者
相似试验
招募中
1 期
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthmaModerate to severe controlled asthma according to Step 4 and Step 5 of the Global Initiative for Asthma (GINA) 2022 Guidelines.MedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2023-503333-22-00Chiesi Farmaceutici S.p.A.777
已完成
3 期
A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Symbicort® 200/6 (budesonide 200 µg plus formoterol 6 µg/actuation), 2 inhalations b.i.d., on parameters of small airway function in patients with Chronic Obstructive Pulmonary Disease.Lung of smoker10037454chronic bronchitisNL-OMON38416Chiesi Farmaceutici170
进行中（未招募）
不适用
Multicentre, randomized research study to test the safety and efficacy of Foster® compared to Symbicort® on small airway function in patients with COPD (Chronic Obstructive Pulmonary Disease)EUCTR2010-022895-30-NLChiesi Farmaceutici S.p.A.170
进行中（未招募）
不适用
A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients. - Double-blind placebo controlled study of escitalopram in the treatment of depression in the elderlyDepression in the elderlyEUCTR2005-003821-25-DKPsychiatric Hospital189
进行中（未招募）
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetesType II DiabetesMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009888-60-BEovartis Pharma Services AG720